Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Nur Nicholson Sells 825 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 825 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $24,354.00. Following the completion of the sale, the insider now owns 83,664 shares of the company’s stock, valued at approximately $2,469,761.28. This represents a 0.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Nur Nicholson also recently made the following trade(s):

• On Wednesday, January 22nd, Nur Nicholson sold 3,948 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $120,137.64.
• On Friday, January 17th, Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $64,264.20.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $30.39 on Friday. The firm has a market capitalization of $3.78 billion, a P/E ratio of -14.97 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm’s fifty day moving average price is $32.24 and its two-hundred day moving average price is $32.95. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the company posted ($1.17) earnings per share. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Trading of Apellis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in shares of Apellis Pharmaceuticals by 23.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after acquiring an additional 735,160 shares during the last quarter. Braidwell LP raised its stake in Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after purchasing an additional 2,513,383 shares in the last quarter. Jennison Associates LLC raised its position in shares of Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after buying an additional 939,289 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Apellis Pharmaceuticals by 191.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares during the period. Finally, Geode Capital Management LLC lifted its position in Apellis Pharmaceuticals by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock worth $52,229,000 after purchasing an additional 22,609 shares during the period. Institutional investors own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on APLS. Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Oppenheimer lowered their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday. Wells Fargo & Company lowered their target price on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Finally, Piper Sandler cut their price target on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).